| Identification | More | [Name]
Bendazac | [CAS]
20187-55-7 | [Synonyms]
(1-BENZYL-1H-INDAZOL-3-YLOXY)-ACETIC ACID
[[1-(phenylmethyl)-1h-indazol-3-yl]oxy]acetic acid
2-(1-BENZYL-1H-INDAZOL-3-YLOXY)ACETIC ACID
AKOS 90683
BENDAZAC
BENDAZAC ACID
[[Benzyl-[1H]-indazol-3-yl] oxy] acetic acid
BENDAZAC AND ITS SODIUM SALT
bendazolic acid
Bindazac
Versus
Zildasac | [EINECS(EC#)]
243-569-2 | [Molecular Formula]
C16H14N2O3 | [MDL Number]
MFCD00866158 | [Molecular Weight]
282.29 | [MOL File]
20187-55-7.mol |
| Chemical Properties | Back Directory | [Melting point ]
161-163°C | [Boiling point ]
424.91°C (rough estimate) | [density ]
1.1658 (rough estimate) | [refractive index ]
1.6240 (estimate) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
2.89±0.10(Predicted) | [color ]
Crystals from ethanol | [λmax]
306nm(lit.) | [Merck ]
14,1035 | [InChIKey]
BYFMCKSPFYVMOU-UHFFFAOYSA-N | [CAS DataBase Reference]
20187-55-7(CAS DataBase Reference) |
| Safety Data | Back Directory | [RTECS ]
AF5085000 | [HS Code ]
2933998090 | [Toxicity]
LD50 in mice, rats (mg/kg): 380, 304 i.v.; 355, 388 i.p.; 440, 910 s.c.; 1105, ~1200 orally (Rx Bulletin) |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Originator]
Versus,Angelini,Italy,1970 | [Uses]
Bendazac is a non-steroidal anti-inflammatory drug (NSAID). Bendazac is often used for joint and muscular pain. Bendazac has potential as an anti-denaturant drug for cataract and other condensation di
seases as it protects proteins from denaturation induced by different agents. | [Definition]
ChEBI: A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties
nd has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts. | [Manufacturing Process]
11 grams of the sodium salt of 1-benzyl-3-oxy-indazole are dissolved in 70 ml
of absolute ethanol by heating the resulting solution to boiling and stirring.
3.5 grams of chloroacetonitrile dissolved in 5 ml of absolute ethanol are then
added within 2-3 minutes and after 10 minutes a further portion of 1.7 grams
of chloroacetonitrile are added. The reaction is finally brought to completion
with an additional 45 minutes of boiling. The reaction mixture is allowed to
cool at room temperature and is then filtered. The alcohol solution is
evaporated to dryness under reduced pressure; the resulting residue is taken
up again with ether and the ether solution is washed in sequence with dilute
HCl, water, NaOH and water. The solution is dried on Na2SO4 and then the
solvent is removed. The residue consists of (1-benzyl-indazole-
3)oxyacetonitrile which is crystallized from methanol. It has a melting point of
93°C.
1 gram of the (1-benzyl-indazole-3)oxyacetonitrile is pulverized and is added
with stirring to 5 ml concentrated HCl. By heating on a boiling water bath for
2-3 minutes, the nitrile product melts and soon thereafter solidifies. The
precipitate is cooled, then filtered and washed well in a mortar with water.
After dissolution in 10% Na2CO3 it is precipitated again with dilute HCl. After crystallization from ethanol, 1-benzyl-indazole-3-oxyacetic acid is obtained. It
has a melting point of 160°C. | [Therapeutic Function]
Antiinflammatory | [Safety Profile]
Poison by intravenous andintraperitoneal routes. Moderately toxic by ingestion andsubcutaneous routes. When heated to decomposition itemits toxic fumes of NOx. |
|
|